Onshoring could threaten the resilient supply chain for biosimilars and generics

Onshoring could threaten the resilient supply chain for biosimilars and generics

Over the past six months, numerous pharmaceutical companies have announced plans to invest in new U.S. manufacturing facilities within the next decade. This so-called “onshoring,” motivated by the Trump administration’s announcement of sector-specific tariffs, seems to make sense on the surface: strengthen domestic manufacturing capabilities and mitigate potential risks of supply disruption. Given the years of time it takes to build a new manufa…